STAASTAAR Surgical Company
Is the price fair?
The yardsticks disagree: cheap against its own 5-year P/E range (19th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.
Cheap vs its own history: P/E 84.6 vs a 107.9 median over 16 quarters (−22% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What STAA's price assumes
STAAR Surgical Company trades at 282× earnings against 40.7× for the median Medical Instruments & Supplies name, more expensive than its own group.
Trailing P/E · Medical Instruments & Supplies median 40.7 · 6.94× the median: the market pays up for this one
- Price / sales
- 3.34
Price / sales · today's price, trailing year to Jul 3, 2026
- Price / book
- 3.10
Price / book · today's price, trailing year to Jul 3, 2026
- EV / sales
- 2.78
EV / sales
Details›
- Price / booktoday's price, trailing year to Jul 3, 2026
- 3.10
- EV / EBITtoday's price, trailing year to Jul 3, 2026
- 68.8
- EV / salestoday's price, trailing year to Jul 3, 2026
- 2.78
- Healthcare median P/E503 names
- 27.9
- Medical Instruments & Supplies median P/E32 names
- 40.7
- Market capitalisation50.1 million shares, counted Aug 7, 2026
- $1.13B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $7.76 |
| Its own P/E history, median | $8.63 |
| Its own P/E history, upper quartile | $11.13 |
| 52-week range | $16.10 – $33.34 |
| Today | $22.60 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Medical Instruments & Supplies
Ranks #9 of 20 by RyuScore